Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Adjuvant Radiotherapy in Low-Risk Breast Cancer Patients: Review and Clinical Implications

June 21st 2015

Over the past several decades, breast-conserving therapy has emerged as the standard of care in the management of early-stage breast cancer.

Novel Small Molecule Inhibitor Shows Promise in HER2+ Breast Cancer With CNS Metastases

June 17th 2015

For insight on the potential of ONT-380 in HER2-positive breast cancer, OncLive spoke with the lead author of the primary phase Ib analysis, Erika P. Hamilton, MD.

Future Approaches in Breast Cancer

June 17th 2015

TNT Study for Triple-Negative or BRCA1/2 Breast Cancer

June 17th 2015

Neratinib in HER2-Positive Breast Cancer

June 17th 2015

Clinical Trials for HER2-Positive Breast Cancer

June 17th 2015

Overcoming Resistance in Breast Cancer

June 17th 2015

Improving Endocrine Treatment Decisions in ER+ Breast Cancer

June 17th 2015

Fulvestrant in HR-Positive Breast Cancer

June 17th 2015

Palbociclib in Metastatic Breast Cancer

June 17th 2015

Tumor-Infiltrating Lymphocytes in Breast Cancer

June 17th 2015

Multigene Panel Testing in Breast Cancer

June 17th 2015

Introduction: Biomarkers in Breast Cancer

June 17th 2015

Dr. Kari Wisinski on Palbociclib for Metastatic Breast Cancer

June 10th 2015

Kari Wisinski, MD, medical oncologist with University Of Wisconsin Health and the University of Wisconsin Carbone Cancer Center, discusses the use of palbociclib for patients with ER-positive and HER2-negative breast cancer.

2015 ASCO Annual Meeting Highlights

June 5th 2015

Dr. Brufsky on Anastrozole Versus Tamoxifen in DCIS

June 3rd 2015

Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief, Division of Hematology/Oncology, co-director, Comprehensive Breast Cancer Center, associate director, Clinical Investigation, University of Pittsburgh, compares the use of anastrozole to tamoxifen in patients with ductal carcinoma in situ (DCIS).

Dr. Cristofanilli on the PALOMA3 Trial for Breast Cancer

June 3rd 2015

Massimo Cristofanilli, MD, Jefferson University Physician, professor, director, Breast Care Center, discusses the PALOMA3 trial.

Neratinib Reduces HER2+ Breast Cancer Recurrences in Phase III ExteNET Study

June 2nd 2015

Treatment with neratinib immediately following adjuvant trastuzumab plus chemotherapy modestly improved invasive disease-free survival against placebo at the cost of low-grade diarrhea in almost all patients with HER2-positive early-stage breast cancer.

Palbociclib More Than Doubles PFS in Pretreated HR+/HER2- Breast Cancer

May 31st 2015

In the phase III PALOMA-3 trial, adding palbociclib to standard fulvestrant more than doubled progression-free survival in pretreated patients with HR-positive, HER2-negative breast cancer.

Hurvitz Looks Back and Ahead at Advances in Treating HER2-Positive Breast Cancer

May 26th 2015

In a recent interview with AJHO, Sara A. Hurvitz, MD, discusses the evolving treatment paradigm of HER2-positive breast cancer and what the future might hold.